{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:32:44Z","timestamp":1788539564131,"version":"build-2803163510"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T00:00:00Z","timestamp":1499040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The NIH R21","award":["CA191751-01"],"award-info":[{"award-number":["CA191751-01"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0180297","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T20:16:50Z","timestamp":1499113010000},"page":"e0180297","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Repositioning Bazedoxifene as a novel IL-6\/GP130 signaling antagonist for human rhabdomyosarcoma therapy"],"prefix":"10.1371","volume":"12","author":[{"given":"Hui","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant Kumar","family":"Bid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengguang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huameng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,7,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00001622-199607000-00008","article-title":"Rhabdomyosarcoma and other soft tissue sarcomas in children","volume":"8","author":"A Pappo","year":"1996","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1542\/peds.2013-3926","article-title":"Cancer incidence rates and trends among children and adolescents in the United States, 2001\u20132009","volume":"134","author":"DA Siegel","year":"2014","journal-title":"Pediatrics"},{"key":"ref3","first-page":"115","article-title":"Rhabdomyosarcoma in adolescent and young adult patients: current perspectives","volume":"5","author":"D Egas-Bejar","year":"2014","journal-title":"Adolescent health, medicine and therapeutics"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.mayocp.2012.01.015","article-title":"Common musculoskeletal tumors of childhood and adolescence","volume":"87","author":"CA Arndt","year":"2012","journal-title":"Mayo Clinic proceedings"},{"key":"ref5","first-page":"37","article-title":"Signal transduction through homo- or heterodimers of gp130","volume":"1","author":"T Kishimoto","year":"1994","journal-title":"Stem Cells"},{"issue":"5115","key":"ref6","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.8511589","article-title":"IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase","volume":"260","author":"M Murakami","year":"1993","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1073\/pnas.91.6.2285","article-title":"Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130","volume":"91","author":"M Narazaki","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"ref8","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.ejca.2005.08.016","article-title":"The role of IL-6 and STAT3 in inflammation and cancer","volume":"41","author":"DR Hodge","year":"2005","journal-title":"Eur J Cancer"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","article-title":"IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer","volume":"22","author":"MF Neurath","year":"2011","journal-title":"Cytokine & growth factor reviews"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molmed.2007.12.007","article-title":"The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer","volume":"14","author":"WE Naugler","year":"2008","journal-title":"Trends in molecular medicine"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/sj.bjc.6600956","article-title":"Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients","volume":"88","author":"T Bachelot","year":"2003","journal-title":"British journal of cancer"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)65348-7","article-title":"Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer","volume":"167","author":"B Andrews","year":"2002","journal-title":"The Journal of urology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-12-26","article-title":"IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus","volume":"12","author":"MF Chen","year":"2013","journal-title":"Molecular cancer"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1535-7163.MCT-12-1082","article-title":"Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer","volume":"12","author":"S Xu","year":"2013","journal-title":"Molecular cancer therapeutics"},{"issue":"7226","key":"ref15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nature07475","article-title":"Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours","volume":"457","author":"S Rebouissou","year":"2009","journal-title":"Nature"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"SA Jones","year":"2011","journal-title":"The Journal of clinical investigation"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1517\/14728222.2013.830105","article-title":"gp130: a promising drug target for cancer therapy","volume":"17","author":"S Xu","year":"2013","journal-title":"Expert opinion on therapeutic targets"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"JF Bromberg","year":"1999","journal-title":"Cell"},{"issue":"13","key":"ref19","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1158\/0008-5472.CAN-05-0317","article-title":"Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3","volume":"65","author":"K Schlessinger","year":"2005","journal-title":"Cancer research"},{"issue":"21","key":"ref20","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/sj.onc.1203476","article-title":"The role of STATs in transcriptional control and their impact on cellular function","volume":"19","author":"J Bromberg","year":"2000","journal-title":"Oncogene"},{"issue":"56","key":"ref21","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1038\/sj.onc.1204086","article-title":"STAT proteins: novel molecular targets for cancer drug discovery","volume":"19","author":"J Turkson","year":"2000","journal-title":"Oncogene"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/sj.onc.1206226","article-title":"Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway","volume":"22","author":"LH Wei","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","article-title":"Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells","volume":"12","author":"T Gritsko","year":"2006","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"50","key":"ref24","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1038\/sj.onc.1206004","article-title":"Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells","volume":"21","author":"PJ Real","year":"2002","journal-title":"Oncogene"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2407-7-111","article-title":"Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells","volume":"7","author":"C Chen","year":"2007","journal-title":"BMC cancer"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1349-7006.2011.01932.x","article-title":"Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells","volume":"102","author":"A Liu","year":"2011","journal-title":"Cancer science"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18632\/oncotarget.930","article-title":"Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo","volume":"4","author":"S Yan","year":"2013","journal-title":"Oncotarget"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1158\/1078-0432.CCR-05-1732","article-title":"Prognostic significance of activated AKT expression in soft-tissue sarcoma","volume":"12","author":"Y Tomita","year":"2006","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1158\/1078-0432.CCR-13-0850","article-title":"Dual blockade of the PI3K\/AKT\/mTOR (AZD8055) and RAS\/MEK\/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo","volume":"19","author":"J Renshaw","year":"2013","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-06-1344","article-title":"Phosphoprotein pathway mapping: Akt\/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival","volume":"67","author":"EF Petricoin 3rd","year":"2007","journal-title":"Cancer research"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.bjc.6603952","article-title":"PDK-1\/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound","volume":"97","author":"L Cen","year":"2007","journal-title":"British journal of cancer"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"J Luo","year":"2003","journal-title":"Cancer cell"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity","volume":"146","author":"BS Komm","year":"2005","journal-title":"Endocrinology"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/13543784.16.10.1663","article-title":"Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis","volume":"16","author":"EM Lewiecki","year":"2007","journal-title":"Expert opinion on investigational drugs"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1358\/dot.2009.45.7.1395293","article-title":"Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis","volume":"45","author":"AA Chines","year":"2009","journal-title":"Drugs Today (Barc)"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/jm401144z","article-title":"Drug Design Targeting Protein-Protein Interactions (PPIs) Using Multiple Ligand Simultaneous Docking (MLSD) and Drug Repositioning: Discovery of Raloxifene and Bazedoxifene as Novel Inhibitors of IL-6\/GP130 Interface","volume":"57","author":"H Li","year":"2014","journal-title":"Journal of medicinal chemistry"},{"issue":"43","key":"ref37","doi-asserted-by":"crossref","first-page":"29514","DOI":"10.1074\/jbc.M109.027896","article-title":"MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction","volume":"284","author":"S Dong","year":"2009","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"ref38","first-page":"279","article-title":"Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells","volume":"38","author":"CC Wei","year":"2011","journal-title":"International journal of oncology"},{"issue":"1\u20132","key":"ref39","first-page":"35","article-title":"MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN","volume":"372","author":"ZL Liu","year":"2013","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4238\/2013.April.2.17","article-title":"MicroRNA-181b expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3","volume":"12","author":"L He","year":"2013","journal-title":"Genetics and molecular research: GMR"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.molcel.2010.07.023","article-title":"STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer","volume":"39","author":"D Iliopoulos","year":"2010","journal-title":"Molecular cell"},{"issue":"13","key":"ref42","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"G Niu","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.onc.1206122","article-title":"Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis","volume":"22","author":"D Wei","year":"2003","journal-title":"Oncogene"},{"issue":"20","key":"ref44","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1038\/sj.onc.1207383","article-title":"Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis","volume":"23","author":"T Xie","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/BF02385807","article-title":"Effect of IL-6 on tumor cell invasion of vascular endothelial monolayers","volume":"27","author":"Y Kitamura","year":"1997","journal-title":"Surgery today"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/1535-7163.MCT-10-0502","article-title":"JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling","volume":"10","author":"L Song","year":"2011","journal-title":"Molecular cancer therapeutics"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/pros.20057","article-title":"Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells","volume":"60","author":"YS Pu","year":"2004","journal-title":"The Prostate"},{"issue":"13","key":"ref48","first-page":"4653","article-title":"Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence","volume":"9","author":"M Trikha","year":"2003","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2011.10.014","article-title":"Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer","volume":"48","author":"K Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"PM Voorhees","year":"2013","journal-title":"British journal of haematology"},{"issue":"8","key":"ref51","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"JF Rossi","year":"2010","journal-title":"British journal of cancer"},{"issue":"32","key":"ref52","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.1021\/bi050439+","article-title":"Binding of madindoline A to the extracellular domain of gp130","volume":"44","author":"AZ Saleh","year":"2005","journal-title":"Biochemistry"},{"issue":"12","key":"ref53","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1210\/en.2008-0817","article-title":"The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention","volume":"149","author":"Y Kharode","year":"2008","journal-title":"Endocrinology"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/PAS.0b013e31826e0271","article-title":"Embryonal rhabdomyosarcoma (botryoid type) of the uterine corpus and cervix in adult women: report of a case series and review of the literature","volume":"37","author":"RF Li","year":"2013","journal-title":"The American journal of surgical pathology"},{"issue":"9","key":"ref55","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1158\/0008-5472.CAN-07-3046","article-title":"The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4'OH-tamoxifen","volume":"68","author":"JA Greenberg","year":"2008","journal-title":"Cancer research"},{"issue":"2","key":"ref56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1525-1438.2007.01025.x","article-title":"The risk of developing uterine sarcoma after tamoxifen use","volume":"18","author":"O Lavie","year":"2008","journal-title":"International journal of gynecological cancer: official journal of the International Gynecological Cancer Society"},{"issue":"1","key":"ref57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/01443610400024740","article-title":"Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer","volume":"25","author":"GC Rieck","year":"2005","journal-title":"Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology"},{"issue":"6","key":"ref58","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women","volume":"16","author":"DF Archer","year":"2009","journal-title":"Menopause"},{"key":"ref59","article-title":"A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture","author":"S Palacios","year":"2015","journal-title":"Menopause"},{"issue":"4","key":"ref60","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.111.072249","article-title":"The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1","volume":"80","author":"JS Lewis-Wambi","year":"2011","journal-title":"Molecular pharmacology"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/en.2012-2038","article-title":"Inhibitory effects of a bazedoxifene\/conjugated equine estrogen combination on human breast cancer cells in vitro","volume":"154","author":"Y Song","year":"2013","journal-title":"Endocrinology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0180297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T08:22:14Z","timestamp":1692865334000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0180297"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,3]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0180297","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,3]]}}}